{"filings":[{"id":95535,"accession_number":"0001171843-26-003156","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q1 net loss $23M; fast track for HBV drug; Amoytop license $25M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Fast Track Designation from FDA for pevifoscorvir sodium for chronic HBV infection.","Phase 2 B-SUPREME interim analysis: DSMB recommended increasing HBeAg- sample size to 100; futility criteria not met.","Exclusive license with Amoytop for Greater China: $25M upfront, up to $420M milestones plus tiered royalties.","Cash, equivalents, investments $54.9M at March 31, 2026 (Dec 31, 2025: $77.8M); expected to fund into Q4 2026 inclusive of $25M upfront.","Net loss Q1 2026: $23.0M ($2.21/share) vs net income $43.1M ($5.12/share) in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":2830000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95534,"accession_number":"0001193125-26-166987","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Aligos licenses pevifoscorvir sodium to Amoytop for China/Taiwan/HK/Macau; upfront $25M, milestones up to $420M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive license to develop and commercialize pevifoscorvir sodium for HBV and HBV/HDV in mainland China, Taiwan, Hong Kong, and Macau.","Upfront cash payment of $25 million from Amoytop; eligible for up to $420 million in development, regulatory, and commercial milestones.","Tiered high single-digit royalties on net sales in the Territory.","Amoytop responsible for all development, regulatory, manufacturing, and commercialization costs in the Territory.","Effectiveness conditional on Amoytop shareholder approval within 45 days of signing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95533,"accession_number":"0001193125-26-154927","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aligos: Phase 2 HBV interim – DSMB ups HBeAg- sample size to 100; FDA Fast Track granted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMB recommended increasing HBeAg- cohort from 74 to 100 participants to optimize power; futility criteria not met.","Study drugs well-tolerated; no viral breakthrough; safety data reviewed across all 174 enrolled participants.","FDA granted Fast Track Designation for pevifoscorvir sodium based on 96-week Phase 1 data.","Topline data from B-SUPREME study remains on track for 2027; enrollment in HBeAg- cohort expected by H2 2026.","Aligos remains blinded to participant-level data; 103 enrolled in HBeAg+ cohort (Part 1a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108677,"accession_number":"0001171843-26-001340","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos reports Q4/FY2025 net loss of $19.9M and $24.2M; cash $77.8M; Phase 2 HBV study progressing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2025 $19.9M ($1.91/sh) vs $82.2M ($13.08/sh) in Q4 2024; FY2025 net loss $24.2M ($2.45/sh) vs $131.2M ($20.94/sh) in FY2024.","Cash, cash equivalents and investments $77.8M as of Dec 31, 2025, up from $56.9M; funding expected into Q3 2026.","Phase 2 B-SUPREME study of pevifoscorvir sodium completed 60 HBeAg- enrollment; topline data expected 2027.","ALG-170675 ASO advanced to IND-enabling studies with partner Amoytop; Amoytop funds China development.","James Hassard appointed EVP, Chief Commercial Officer; ALG-055009 preclinical data showed synergistic weight loss with incretins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108676,"accession_number":"0001193125-26-037558","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aligos Therapeutics appoints Nikhil Aneja as Principal Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nikhil Aneja appointed Principal Accounting Officer effective January 29, 2026.","He succeeds Lesley Ann Calhoun, who remains EVP, COO & CFO.","Aneja has served as VP Finance since Feb 2024; prior roles at CareDx, Blade Therapeutics, Global Blood Therapeutics.","Aneja, age 49, is a CPA with a Bachelor of Commerce from University of Delhi."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125123,"accession_number":"0001171843-25-007075","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q3 net loss $31.5M; Phase 2 HBV study enrolling; cash $99.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $31.5M in Q3 2025 vs $19.3M in Q3 2024; diluted EPS loss of $3.04.","Cash, cash equivalents and investments $99.1M as of Sep 30, 2025; runway into Q3 2026.","Phase 2 B-SUPREME trial of pevifoscorvir sodium (CAM-E) for chronic HBV enrolled first patient Aug 2025; interim data 2026.","Preclinical combo data with ALG-055009 (THR-β) and incretin RAs showed synergistic weight loss; out-licensing discussions ongoing.","R&D expenses rose to $23.9M (from $16.8M) driven by Phase 2 costs; G&A $5.2M (from $4.6M) due to legal."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":2017000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141834,"accession_number":"0001171843-25-005116","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q2 net loss $15.9M, cash $122.9M; Phase 2 HBV study dosing imminent","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.9M ($1.53/sh) vs net income of $5.1M ($0.81/sh) in Q2 2024, driven by change in warrant fair value.","Cash, cash equivalents and investments $122.9M as of June 30, 2025, expected to fund operations into H2 2026.","Phase 2 B-SUPREME study of ALG-000184 (HBV) starting; interim data expected 2026, topline 2027.","ALG-055009 (MASH) Phase 2a data presented; company evaluating partnership options for continued development.","R&D expenses fell to $14.0M from $21.1M YoY due to MASH trial completion, offset by HBV program spend."],"consensus_eps_estimate":null,"consensus_eps_actual":2.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":1276000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159762,"accession_number":"0001193125-25-148905","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Aligos stockholders approve charter amendments increasing authorized shares 5x and 2020 Plan share reserve by 1M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved increase in authorized voting common stock from 20M to 100M shares.","Stockholders approved increase in authorized non-voting common stock from 800k to 15.8M shares.","Stockholders approved amendment to 2020 Plan adding 1M shares to the share reserve.","All three Class II director nominees (Hirth, Preston, Chavez) were elected with ~2.16M votes for.","Ratification of Ernst & Young as independent auditor for FY2025 approved with 3.43M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159761,"accession_number":"0001171843-25-002781","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos raises >$100M, posts Q1 net income $43.1M; HBV drug Phase 2 to start mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash grew to $137.9M after raising over $100M; expected to fund operations into H2 2026.","Q1 2025 net income $43.1M (basic EPS $5.12); diluted net loss per share ($2.11) due to warrant fair value change.","Phase 2 B-SUPREME study of ALG-000184 in chronic HBV expected to begin mid-2025; interim data 2026, topline 2027.","ALG-055009 (THR-β agonist) Phase 2a HERALD showed placebo-adjusted median liver fat reduction up to 46.2%; up to 70% subjects achieved ≥30% reduction.","ALG-097558 pan-coronavirus inhibitor has 3 clinical trials ongoing; NIAID study Q2 2025. Company seeking external funding for further development."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":311000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178138,"accession_number":"0001171843-25-001352","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q4 net loss $82.2M; cash $56.9M; ALG-000184 Phase 2 mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $82.2M ($13.08/share) vs $27.9M ($5.50) in Q4 2023; full-year net loss $131.2M vs $87.7M.","Cash & investments $56.9M at Dec 31, 2024; $105M private placement closed Feb 2025 extends runway into H2 2026.","Lead CAM-E candidate ALG-000184 Phase 2 expected to start mid-2025; 96-week data to be presented in 2025.","THR-β agonist ALG-055009 for MASH showed up to 46.2% placebo-adjusted median relative liver fat reduction at Week 12.","Lesley Ann Calhoun promoted to EVP, COO and CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178137,"accession_number":"0001193125-25-024838","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Aligos Therapeutics secures $105M private placement to fund Phase 2 hepatitis B study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$105M from sale of 2.1M shares, pre-funded warrants (1.9M shares), and warrants (2.0M shares); closing expected Feb 13, 2025.","Combined price $26.0825 per share/warrant; warrants exercisable at $26.02, expire Feb 13, 2032; pre-funded warrants at $0.0001.","Net proceeds to fund ALG-000184 Phase 2 study in chronic hepatitis B; cash runway extended into H2 2026.","Placement led by life sciences investor; Jefferies and Piper Sandler as agents; lead investor gets board nomination rights.","Company to file resale registration statement within 45 days; securities sold in private placement exempt from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178136,"accession_number":"0001193125-25-019256","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aligos Therapeutics appoints Lesley Ann Calhoun as COO while retaining CFO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lesley Ann Calhoun appointed COO effective January 30, 2025, adding to existing CFO role.","She has served as EVP and CFO since June 2020; prior roles at Global Blood Therapeutics and Hyperion Therapeutics.","Calhoun brings over 30 years of finance and operations experience, including audit at Deloitte & Touche."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194800,"accession_number":"0001171843-24-006057","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q3 net loss $19.3M; MASH drug shows up to 46.2% liver fat reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.3M ($3.07 per share) vs $18.0M ($10.37 per share) in Q3 2023.","Cash & investments $74.9M, down from $135.7M at Dec 31, 2023; runway through end of 2025.","MASH candidate ALG-055009 achieved placebo-adjusted median relative liver fat reduction up to 46.2% at Week 12; favorable tolerability.","CHB candidate ALG-000184 progressing to Phase 2 next year; FDA and China NMPA agree on primary endpoint.","COVID protease inhibitor ALG-097558 to begin externally funded clinical studies in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":3005000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211094,"accession_number":"0001193125-24-214188","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aligos Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Sept 3, 2024 confirming compliance with Minimum Bid Price Requirement.","Previous deficiency letter was dated Sept 5, 2023; stock had closed below $1.00 for 30 consecutive days.","Compliance achieved under Nasdaq Listing Rules 5450(a)(1) and 5550(a)(2); matter is closed.","No additional financial or operational details provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211093,"accession_number":"0001193125-24-202813","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Aligos Therapeutics effects 1-for-25 reverse stock split to meet Nasdaq listing requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1-for-25 effective 12:01 a.m. ET on August 19, 2024; trading symbol ALGS unchanged.","Split intended to bring company into compliance with Nasdaq minimum bid price for continued listing.","Every 25 pre-split shares reclassified into one new share; par value unchanged at $0.0001.","No fractional shares issued; holders entitled to cash payment based on August 16, 2024 closing price.","Board approved split on July 24, 2024; final ratio set by Reverse Split Committee on August 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211092,"accession_number":"0001193125-24-196966","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aligos appoints Heather Preston and Margarita Chavez to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to seven directors; Preston and Chavez appointed as Class II directors through 2025 annual meeting.","Dr. Preston will chair the Nominating Committee; Ms. Chavez joins the Audit Committee.","Each receives $40k annual retainer (prorated) and an initial option for 120,000 shares.","Chavez gets additional $7,500/yr for Audit; Preston gets $8,000/yr for Nominating chair (both prorated).","Both entered standard indemnification agreements; no material relationships requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211091,"accession_number":"0001171843-24-004482","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q2 net income $5.1M on warrant revaluation; HERALD topline due early Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $94.5M at June 30, down from $135.7M year-end; runway through end of 2025.","Net income of $5.1M ($0.03/sh) vs net loss of $18.8M (-$0.43) YoY; non-cash warrant income $30.5M.","R&D spend $21.1M (+26% YoY) on clinical trial costs; G&A $6.4M (-30% YoY).","ALG-055009 (MASH) HERALD enrollment complete; topline data expected early Q4 2024.","ALG-000184 (CHB) showed sustained HBV DNA suppression in 90-100% of subjects; FDA supports registration endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":1755000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229609,"accession_number":"0001193125-24-172218","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Aligos stockholders approve increase in authorized shares from 300M to 500M and amendment to 2020 incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved increase in authorized shares from 300M to 500M, effective June 27, 2024.","Approved amendment to 2020 incentive plan to treat pre-funded warrants with exercise price ≤ $0.01 as common stock for annual share increases.","Board authorized to effect reverse stock split if deemed in best interests; no immediate action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229608,"accession_number":"0001193125-24-151729","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aligos receives Nasdaq notice for Audit Committee noncompliance; cure period to Nov 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Jack Nielsen resigned from Board and Audit Committee on May 21, 2024, causing noncompliance with Rule 5605.","Nasdaq granted cure period until Nov 18, 2024, as next annual meeting is June 27, 2024.","Company plans to appoint a third independent director to the Audit Committee before the cure deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229607,"accession_number":"0001193125-24-144929","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Jack Nielsen resigns from board; Aligos out of compliance with Nasdaq Audit Committee rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Director Jack Nielsen resigned effective May 21, 2024 for personal reasons; no disagreement with company.","Audit Committee now has two members; Nasdaq requires three under Rule 5605(c)(2)(A).","Company notified Nasdaq of non-compliance on May 22, 2024 and plans to cure within 180-day period.","Aligos intends to appoint a qualified third director to Audit Committee within the cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229606,"accession_number":"0001193125-24-139476","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aligos Therapeutics Chief Medical Officer Matthew McClure resigns effective May 9, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew McClure resigned as Chief Medical Officer on May 9, 2024.","No replacement or interim CMO was announced in the filing.","The departure follows Aligos's focus on antiviral therapeutics; impact on pipeline unclear."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229605,"accession_number":"0001171843-24-002612","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q1 net loss $34.9M; Phase 2a HERALD study commenced, topline expected Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $34.9M ($0.22 per share) vs $23.0M ($0.53) in Q1 2023; increase due to non-cash warrant liability charge.","Cash and investments $112.7M, down from $135.7M at Dec 2023; runway through end of 2025.","Phase 2a HERALD study (ALG-055009 for MASH) started dosing April 2024; topline data expected Q4 2024.","Received additional $1.3M NIH grant for pan-coronavirus protease inhibitor ALG-097558; Phase 2 enabling activities underway."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":694000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248135,"accession_number":"0001171843-24-001294","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q4 net loss $27.9M ($0.22/sh); cash $135.7M; HERALD data expected Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $135.7M as of Dec 31, 2023; raised $92.1M in Oct 2023 PIPE; runway through end of 2025.","Q4 2023 net loss $27.9M ($0.22/sh) vs $21.9M ($0.51/sh) in Q4 2022; full year net loss $87.7M ($1.36/sh).","ALG-055009 Phase 2a HERALD (MASH) first subject dosed expected Q2 2024; topline data anticipated Q4 2024.","ALG-000184 (CHB) Phase 1b continues; interim data presentations planned at APASL, EASL, AASLD 2024.","ALG-097558 pan-coronavirus protease inhibitor Phase 1 nearing completion; topline data at ECCMID April 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248134,"accession_number":"0001193125-24-050987","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aligos Therapeutics completes stock option exchange; 93% of eligible underwater options surrendered.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Option exchange program closed; 3,880,332 shares surrendered (~93% of eligible) for 1,906,153 replacement options.","CEO Lawrence M. Blatt surrendered 854,250 options, received 421,100 replacement options; other NEOs and directors also participated.","Exchange ratios were 1.4-for-1 or 3.4-for-1 based on exercise price; all surrendered options were underwater.","Replacement options have a new one-year cliff vest from grant date (Feb 28, 2024), then follow original schedule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}